NCT04082754View on ClinicalTrials.gov

A Clinical Study to Test the Safety, Exposure, and Pharmacodynamic Markers of CSL311 in Patients With Mild-to-moderate Asthma and in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

November 28, 2019

Primary Completion Date

November 14, 2023

Study Completion Date

November 14, 2023

Conditions
Asthma
Interventions
BIOLOGICAL

Human beta common receptor antagonist monoclonal antibody

Human beta common receptor antagonist monoclonal antibody

DRUG

Placebo

0.9% sodium chloride, same volume and same duration as CSL311

Trial Locations (3)

30625

Fraunhofer-Institut für Toxikologie und Experimentelle Medizin ITEM, Hanover

Unknown

Paraxel Berlin, Berlin

M23 9QZ

Medicines Evaluation Unit, Manchester

Sponsors

Lead Sponsor

CSL Behring
All Listed Sponsors
lead

CSL Behring

INDUSTRY